Stock listing

NASDAQ:ADPT Adaptive Biotechnologies Corporation Stock

Home listing (NASDAQ) of Adaptive Biotechnologies Corporation

Follow Adaptive Biotechnologies Corporation into a list and get an email when it puts out news.

Share price · NASDAQ:ADPT

$27.93 USD -0.53 (-1.9%)

Close on Nov 20, 2026

Past year +71.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$27.15 – $28.23 USDNov 20, 2026
Volume
2.48M sharesNov 20, 2026
Market cap
$4.52B USDAt the close on Nov 20, 2026 · price × 161.9M shares outstanding
52-week range
$12.00 – $32.21 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$59.31M USDMedian day 1.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Adaptive Biotechnologies Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ADPT · Home$27.93 USD-0.53 (-1.9%)2,483,129$27.43$28.23$27.15$28.46Close on Nov 20, 2026
Dusseldorf:1HM€25.07 EUR-0.61 (-2.4%)—€25.07€25.07€25.07€25.68Close on Nov 20, 2026
Frankfurt:1HM€25.74 EUR+0.16 (+0.6%)—€25.74€25.74€25.74€25.58Close on Nov 19, 2026
Munich:1HM€25.79 EUR0.00 (0.0%)—€25.79€25.79€25.79€25.79Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ADPT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$27.93-0.53-1.9%$27.43$28.23$27.152,483,129
$28.46-0.03-0.1%$27.79$29.23$27.622,209,989
$28.49+0.62+2.2%$28.00$29.18$27.621,886,344
$27.87-1.17-4.0%$28.26$28.52$27.292,657,887
$29.04-0.44-1.5%$29.69$29.78$28.392,058,038
$29.48-0.46-1.5%$29.20$29.78$28.591,914,519
$29.94+0.58+2.0%$30.06$32.21$29.832,645,750
$29.36-0.90-3.0%$30.00$30.81$28.941,849,485
$30.26+2.28+8.1%$28.53$30.79$28.232,831,533
$27.98+1.15+4.3%$26.98$28.27$26.543,333,525
$26.83+0.12+0.4%$28.11$28.11$25.474,045,316
$26.71+0.91+3.5%$26.42$26.88$25.192,328,994
$25.80+0.74+3.0%$25.46$26.46$25.331,512,838
$25.06-1.58-5.9%$26.98$27.44$24.802,327,029
$26.64-1.53-5.4%$27.36$27.97$26.174,256,397
$28.17-0.20-0.7%$28.00$28.81$27.912,588,866
$28.37+0.71+2.6%$27.28$29.05$27.282,317,529
$27.66+1.39+5.3%$26.36$28.00$26.051,516,848
$26.27+0.76+3.0%$25.66$26.45$25.241,151,916
$25.51+1.10+4.5%$24.23$25.62$23.821,922,107
$24.41-0.92-3.6%$25.39$25.68$23.911,255,850
$25.33+0.91+3.7%$24.36$25.74$24.251,704,200
$24.42+0.47+2.0%$24.07$24.89$23.851,245,345
$23.95-0.07-0.3%$24.30$24.88$23.861,187,864
$24.02-1.56-6.1%$25.41$25.65$23.951,947,565
$25.58-0.04-0.2%$25.47$25.91$24.881,734,427
$25.62+0.34+1.3%$24.59$26.33$24.331,884,113
$25.28-0.29-1.1%$25.38$25.86$24.661,954,784
$25.57-0.92-3.5%$26.31$26.49$24.763,121,956
$26.49+0.40+1.5%$26.11$26.85$25.971,525,258
$26.09-0.19-0.7%$26.00$26.14$25.122,646,924
$26.28-0.62-2.3%$26.39$26.93$25.872,120,225
$26.90-2.94-9.9%$30.22$30.74$26.852,533,775
$29.84+1.49+5.3%$28.57$29.86$28.161,425,150
$28.35+0.98+3.6%$27.59$28.41$27.311,575,446
$27.37-1.53-5.3%$28.89$29.00$27.156,018,788
$28.90+0.13+0.5%$28.80$29.52$28.751,508,275
$28.77+0.26+0.9%$29.28$29.80$28.632,508,234
$28.51-0.92-3.1%$29.00$29.52$28.072,638,957
$29.43-0.14-0.5%$29.96$29.96$28.881,686,003
$29.57+1.68+6.0%$28.00$29.58$27.503,610,497
$27.89-0.17-0.6%$27.74$28.35$27.601,079,717
$28.06+0.20+0.7%$27.30$28.36$26.734,000,158
$27.86-0.75-2.6%$28.69$28.78$27.701,458,727
$28.61+0.06+0.2%$28.55$28.68$27.912,985,539
$28.55+0.88+3.2%$28.23$28.72$27.773,279,757
$27.67+0.99+3.7%$27.09$28.72$27.035,026,486
$26.68+1.90+7.7%$24.80$27.34$24.714,124,280
$24.78+0.58+2.4%$24.26$24.88$23.971,730,383
$24.20-0.03-0.1%$24.23$24.79$23.931,238,268
$24.23-0.19-0.8%$23.81$24.65$23.531,071,432
$24.42+0.08+0.3%$24.05$24.68$23.891,106,844
$24.34+0.06+0.2%$23.98$24.60$23.621,358,580
$24.28-0.29-1.2%$24.06$24.40$23.941,404,316
$24.57-0.09-0.4%$25.18$25.36$23.842,161,036
$24.66+0.32+1.3%$24.40$25.23$24.191,623,149
$24.34-0.58-2.3%$24.91$25.11$24.201,621,010
$24.92-0.27-1.1%$24.61$25.02$23.872,237,634
$25.19-1.25-4.7%$26.54$26.58$25.131,509,096
$26.44+0.28+1.1%$26.23$26.87$26.111,944,721
$26.16-0.09-0.3%$26.00$26.51$25.821,387,277
$26.25+0.70+2.7%$25.81$26.49$25.231,221,787
$25.55-0.44-1.7%$25.80$25.99$25.091,694,427
$25.99+0.55+2.2%$25.37$26.03$24.931,816,948
$25.44-0.05-0.2%$24.78$26.09$24.781,966,210
Ticker
NASDAQ:ADPT
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Adaptive Biotechnologies Corporation news

Adaptive Biotechnologies Corporation on 6ix

News releases
32 in the last 12 months · 181 in all · newest Nov 18, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 4, 2026
Decks
32 decks · latest May 5, 2026

Where Adaptive Biotechnologies Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:ADPT · Home listing · This pageNASDAQUnited StatesUSD
gettex:1HMgettexGermanyEUR
LS Exchange:A2PLR5LS ExchangeGermanyEUR
Lang & Schwarz:A2PLR5Lang & SchwarzGermanyEUR
Tradegate:1HMTradegateGermanyEUR
BOATS:ADPTBOATSUnited StatesUSD
Dusseldorf:1HMDusseldorfGermanyEUR
Frankfurt:1HMFrankfurtGermanyEUR
Hamburg:1HMHamburgGermanyEUR
Munich:1HMMunichGermanyEUR
Stuttgart:1HMStuttgartGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.22B USD
P/E
Loss
EV/sales
14.2×
EV/EBITDA
Negative EBITDA
Price/book
25.7×
Gross margin
74.0%
Operating margin
−16.2%
Net margin
−23.7%
Debt to equity
0.0×
Beta vs S&P 500
1.39

Forecasts

6 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
32.57 USD · Analysts' mean
EPS, year to Dec 2026
-0.37 · 1 analyst
Revenue, year to Dec 2026
307M · 7 analysts

Team and board

Officers

OfficerRole
Chad RobinsChief Executive Officer, Co-founder, Chairman of the Board
Kyle PiskelChief Financial Officer
Julie RubinsteinPresident & Chief Operating Officer
ADAPTIVE INVESTORSKarina CalzadillaVice President, Investor Relations and FP&
ADAPTIVE MEDIAErica JonesAssociate Corporate Communications
Erica JonesAssociate Corporate Communications Director
Karina CalzadillaVice President, Investor Relations and FP&A
Clarice McCauleyVP, Head of Legal
Mary Pat LancelottaSenior Vice President, Global Market and Business Development
Francis LoChief People Officer
Sharon BenzenoChief Commercial Officer, Immune Medicine
Susan BobulskyChief Commercial Officer, MRD

Board

DirectorRole
Chad RobinsChief Executive Officer, Co-founder, Chairman of the Board
Katey OwenBoard Member
Michelle GriffinBoard Member
Peter NeupertBoard Member
Robert HershbergBoard Member

Events

Calls

CallWhenStatus
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2026 Earnings CallWed, Jul 29, 2026 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2025 Earnings CallThu, Feb 05, 2026 · 7:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2025 Earnings CallWed, Nov 05, 2025 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2025 Earnings CallTue, Aug 05, 2025 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2025 Earnings CallThu, May 01, 2025 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2024 Earnings CallTue, Feb 11, 2025 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
All 27 calls
CallWhenStatus
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2024 Earnings CallTue, May 07, 2024 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2023 Earnings CallWed, Feb 14, 2024 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2023 Earnings CallThu, Nov 09, 2023 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2023 Earnings CallWed, Aug 02, 2023 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2023 Earnings CallWed, May 03, 2023 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2022 Earnings CallTue, Feb 14, 2023 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2022 Earnings CallWed, Aug 03, 2022 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2021 Earnings CallTue, Feb 15, 2022 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2021 Earnings CallWed, Nov 03, 2021 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2021 Earnings CallWed, Aug 04, 2021 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2021 Earnings CallWed, May 05, 2021 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2020 Earnings CallWed, Feb 24, 2021 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2020 Earnings CallTue, Nov 10, 2020 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2020 Earnings CallTue, Aug 11, 2020 · 4:30 PM ETReplay
Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2020 Earnings CallTue, May 12, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close+0.5%
Q2 2026Jul 29, 2026 · After close+7.2%
Q1 2026May 5, 2026 · After close+4.7%
Q4 2025Feb 5, 2026 · After close−4.3%
Q3 2025Nov 5, 2025 · After close−11.5%
Q2 2025Aug 5, 2025 · After close+5.8%
Q1 2025May 1, 2025 · After close+33.7%
Q4 2024Feb 11, 2025 · After close−3.2%
Q3 2024Nov 7, 2024 · After close+3.4%
Q2 2024Aug 1, 2024 · After close−3.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close+2.3%
Q4 2023Feb 14, 2024 · After close+0.5%
Q3 2023Nov 9, 2023 · After close−18.2%
Q2 2023Aug 2, 2023 · After close−12.4%
Q1 2023May 3, 2023 · After close−14.3%
Q4 2022Feb 14, 2023 · After close+15.6%
Q3 2022Nov 3, 2022 · After close+14.3%
Q2 2022Aug 3, 2022 · After close+14.9%
Q1 2022May 4, 2022 · After close−4.3%
Q4 2021Feb 15, 2022 · After close+5.2%

Open Events

Decks

DeckKindSlidesDate
Q1 2026 Earnings PresentationEarnings31 slidesMay 5, 2026
Q4 2025 Earnings PresentationEarnings15 slidesFeb 5, 2026
J.P. Morgan Healthcare Conference 2026Conference24 slidesJan 12, 2026
Q1 2026 Earnings PresentationEarnings11 slides2026
Q2 2026 Earnings PresentationEarnings13 slides2026
Q1 2025 Earnings PresentationEarnings13 slidesMay 1, 2025
Q4 2024 Earnings PresentationEarnings17 slidesFeb 11, 2025
J.P. Morgan Healthcare Conference 2025Conference23 slidesJan 14, 2025
Q2 2025 Earnings PresentationEarnings15 slides2025
Q3 2025 Earnings PresentationEarnings13 slides2025
All 32 decks
DeckKindSlidesDate
Q3 2024 Earnings PresentationEarnings11 slidesNov 7, 2024
Q2 2024 Earnings PresentationEarnings11 slidesAug 1, 2024
Q1 2024 Earnings PresentationEarnings12 slidesMay 7, 2024
Q4 2023 Earnings PresentationEarnings17 slidesFeb 14, 2024
J.P. Morgan Healthcare Conference 2024Conference23 slides2024
Q3 2023 Earnings PresentationEarnings10 slidesNov 9, 2023
Q2 2023 Earnings PresentationEarnings13 slidesAug 2, 2023
Q1 2023 Earnings PresentationEarnings12 slidesMay 3, 2023
Q4 2022 Earnings PresentationEarnings16 slides2023
William Blair Growth Stock Conference 2023Conference22 slides2023
Q4 2021 Earnings PresentationEarnings15 slides2022
William Blair Growth Stock Conference 2022Conference27 slides2022
JPM 2022 Healthcare ConferenceConference23 slides2022
Q1 2022 Earnings PresentationEarnings19 slides2022
Q3 2022 Earnings PresentationEarnings16 slides2022
Q2 2022 Earnings PresentationEarnings14 slides2022
Q2 2021 Earnings PresentationEarnings11 slides2021
JPM 2021 Healthcare ConferenceConference26 slidesJanuary 2021
Q3 2021 Earnings PresentationEarnings10 slides2021
Q1 2021 Earnings PresentationEarnings13 slides2021
Q3 2020 Earnings PresentationEarnings14 slidesNov 10, 2020
Cowen Liquid Biopsy Summit 2020Conference12 slidesSep 24, 2020

Open Decks

Financings

RaiseDate
0% convertible senior notes due 2031
Made bigger: US$300M · J. Wood Capital Advisors LLC
Dealers: J. Wood Capital Advisors LLC
Use of proceeds: Capped call transactions, repurchase of $25 million of common stock, repayment of the OrbiMed Purchase Agreement, general corporate purposes and MRD initiatives
Jun 17, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$20.00 a share on Jun 26, 2019.

Price
US$20.00 a share
Shares offered
15,000,000 shares of common stock
Offering size
US$300 million
Underwriters' option
Up to 2,250,000 more shares
Underwriters
Goldman Sachs & Co. LLC, J.P. Morgan, BofA Merrill Lynch, Cowen, Guggenheim Securities, William Blair, BTIG · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 29, 2019
Filed publiclyMay 30, 2019
Amended 3 timesNewest Jun 26, 2019
Shares registered with an exchangeJun 26, 2019
Declared effective by the SECJun 26, 2019
Final prospectus, with the priceJun 27, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Jun 27, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue277.0M179.0M170.3M185.3M154.3M98.4M85.1M55.7M38.4M
Cost of revenue71.4M72.1M75.6M57.9M49.3M22.5M22.3M19.7M15.7M
Gross profit205.6M106.9M94.7M127.4M105.0M75.9M62.8M36.0M22.8M
Research and development93.8M103.0M122.1M141.8M142.3M116.1M70.7M39.2M32.0M
Selling, general and administrative72.7M72.8M83.9M88.5M74.5M49.5M30.3M20.4M15.9M
Operating income-57.1M-162.5M-227.0M-200.2M-209.0M-152.8M-78.4M-49.8M-44.5M
Depreciation and amortization16.0M17.4M19.6M20.9M12.3M6.77M6.09M4.30M4.10M
EBITDA-41.1M-145.1M-207.4M-179.3M-196.7M-146.0M-72.3M-45.5M-40.4M
Interest expense11.8M11.6M13.8M4.24M1.67M0000
Income before tax-59.5M-159.6M-225.3M-200.4M-207.3M-146.2M-68.6M-46.4M-42.8M
Income tax000-57.9M-1.69M-6.59M03.31M-804.0K
Net income-59.5M-159.5M-225.3M-200.2M-207.3M-146.2M-68.6M-46.4M-42.8M
Earnings per share, basic-0.39-1.08-1.56-1.40-1.48-1.11-1.01-3.67-3.50
Earnings per share, diluted-0.39-1.08-1.56-1.40-1.48-1.11-1.01-3.67-3.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents70.5M47.9M65.1M90.0M139.1M123.4M96.6M55.0M85.3M
Short-term investments156.5M174.4M281.3M408.2M214.0M564.8M480.3M110.0M106.8M
Receivables50.4M41.7M38.0M40.1M17.4M10.0M12.7M4.81M5.58M
Inventory9.82M8.44M14.4M14.5M19.3M14.1M9.07M7.84M4.79M
Current assets300.2M283.8M410.2M562.1M402.7M726.9M612.7M180.7M205.2M
Property, plant and equipment34.1M48.6M68.2M83.4M85.3M39.7M60.4M19.1M14.0M
Goodwill119.0M119.0M119.0M119.0M119.0M119.0M119.0M119.0M119.0M
Total assets512.7M539.4M661.1M856.6M923.3M1.12B912.3M332.7M362.5M
Accounts payable6.47M7.26M7.72M8.08M3.31M3.24M4.45M1.79M1.96M
Current liabilities89.9M98.1M88.0M109.8M113.8M105.2M78.3M22.8M21.0M
Long-term debt126.6M132.4M130.7M125.4M336.0K342.0K
Total debt131.2M133.3M130.7M125.4M111.7M107.9M36.6M561.2M561.7M
Total liabilities287.7M336.9M352.9M392.5M319.2M373.1M341.3M29.9M587.1M
Shareholders' equity218.8M202.7M308.4M464.2M604.0M743.3M571.0M-258.1M-224.6M
Shares outstanding153.8M147.8M145.1M143.1M141.4M137.6M125.2M12.8M139.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-46.0M-95.2M-156.3M-183.9M-192.7M-149.7M205.4M-32.3M-34.9M
Capital spending-2.96M-3.66M-10.7M-16.3M-61.7M-18.8M-11.2M-6.30M-2.42M
Free cash flow-48.9M-98.9M-167.0M-200.3M-254.5M-168.5M194.2M-38.6M-37.3M
Cash from investing38.0M77.8M129.6M2.90M181.2M-117.0M-481.7M736.0K36.4M
Cash from financing30.4M241.0K2.25M132.3M27.1M293.6M319.9M1.25M50.0M
Dividends paid00
Share buybacks7.89M26.7M293.6M324.9M1.27M50.0M
Change in cash22.4M-17.2M-24.4M-48.8M15.6M26.9M43.6M-30.3M51.6M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 29, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
144 · Notice of proposed saleJul 30, 2026Other filingsSEC
8-K · Current reportJul 29, 2026ResultsSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
144 · Notice of proposed saleJul 16, 2026Other filingsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
8-K · Current reportJun 22, 2026Material contractSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
8-K · Current reportJun 15, 2026Current reportSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
8-K · Current reportJun 9, 2026Meeting outcomeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
144 · Notice of proposed saleMar 10, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 27, 2026Offer documentSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
8-K · Current reportFeb 5, 2026ResultsSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4/A · Change in ownership, amendedJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
8-K · Current reportDec 30, 2025Current reportSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
144 · Notice of proposed saleNov 28, 2025Other filingsSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
8-K · Current reportAug 18, 2025Current reportSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 9, 2025Big-stake noticeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 6, 2025Big-stake noticeSEC

This page holds 200 of 839 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Adaptive Biotechnologies Corporation’s releases · as of Oct 30, 2026

Common shares
161,876,694
Fully diluted
161,876,694

Fully diluted

LineSharesAs of
Common shares161,876,694Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026161,876,694

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Viking Global Investors LP30MUS$867MSep 30, 2026
BlackRock15.3MUS$442MSep 30, 2026
Vanguard12.8MUS$371MSep 30, 2026
T. Rowe Price9.29MUS$268MSep 30, 2026
D. E. Shaw & Co., Inc.6.37MUS$184MSep 30, 2026
Wellington4.75MUS$137MSep 30, 2026
Driehaus Capital Management LLC4.71MUS$136MSep 30, 2026
Geode Capital3.72MUS$108MSep 30, 2026
State Street3.56MUS$103MSep 30, 2026
Lord, Abbett & Co. LLC3.32MUS$95.9MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Invesco3.23MUS$93.3MSep 30, 2026
Goldman Sachs3.09MUS$89.2MSep 30, 2026
BNP Paribas3.08MUS$89MSep 30, 2026
Principal2.45MUS$70.7MSep 30, 2026
Nuveen2.34MUS$67.7MSep 30, 2026
Arrowstreet Capital, Limited Partnership2.31MUS$66.8MSep 30, 2026
Fred Alger Management, LLC2.08MUS$60MSep 30, 2026
ARK1.92MUS$55.5MSep 30, 2026
UBS1.86MUS$53.8MSep 30, 2026
Aristotle Atlantic Partners, LLC1.85MUS$53.6MSep 30, 2026
Westfield Capital Management Co LP1.83MUS$52.8MSep 30, 2026
Northern Trust1.53MUS$44.2MSep 30, 2026
Oberweis Asset Management Inc/1.26MUS$36.3MSep 30, 2026
Schwab1.24MUS$36MSep 30, 2026
Millennium1.22MUS$35.1MSep 30, 2026
Nomura1.21MUS$35.1MSep 30, 2026
Bank of America1.14MUS$33.1MSep 30, 2026
Ameriprise1.13MUS$32.7MSep 30, 2026
Amova Asset Management Americas, Inc.1.09MUS$31.4MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.1.09MUS$31.4MSep 30, 2026
Morgan Stanley1.05MUS$30.4MSep 30, 2026
BNY1.03MUS$29.8MSep 30, 2026
Panagora Asset Management Inc1.02MUS$29.5MSep 30, 2026
Blue Water Life Science Advisors, LP1.01MUS$29.2MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.947KUS$27.4MSep 30, 2026
Renaissance Technologies867KUS$25.1MSep 30, 2026
Fidelity833KUS$24.1MSep 30, 2026
First Trust797KUS$23MSep 30, 2026
abrdn783KUS$22.6MSep 30, 2026
Mackenzie740KUS$21.4MSep 30, 2026
Sun Life708KUS$20.4MSep 30, 2026
Franklin Templeton705KUS$18.8MSep 30, 2026
Qube Research & Technologies Ltd696KUS$20.1MSep 30, 2026
Susquehanna634KUS$18.3MSep 30, 2026
Point72 Asset Management, L.P.630KUS$18.2MSep 30, 2026
Granite Investment Partners, LLC628KUS$18.2MSep 30, 2026
Next Century Growth Investors LLC623KUS$18MSep 30, 2026
Jennison Associates LLC612KUS$17.7MSep 30, 2026
Parkman Healthcare Partners LLC600KUS$17.3MSep 30, 2026
Hillsdale Investment Management Inc.551KUS$15.9MSep 30, 2026

This page holds 50 of 321 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund4.83MUS$104MJun 30, 2026
iShares Russell 2000 ETF3.96MUS$84.8MJun 30, 2026
ARK Genomic Revolution ETF1.77MUS$40.1MJul 31, 2026
Vanguard Small-Cap Index Fund1.74MUS$37.4MJun 30, 2026
Fidelity Small Cap Index Fund1.68MUS$38MJul 31, 2026
Alger Small Cap Focus Fund1.49MUS$33.7MJul 31, 2026
iShares Russell 2000 Growth ETF1.42MUS$30.5MJun 30, 2026
Vanguard Extended Market Index Fund1.42MUS$30.4MJun 30, 2026
Oberweis Micro-Cap Fund1.25MUS$26.1MJun 30, 2026
Lord Abbett Developing Growth Fund Inc1.19MUS$27MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Invesco Main Street Small Cap Fund1.1MUS$23.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.1MUS$23.6MJun 30, 2026
iShares Biotechnology ETF1.09MUS$23.5MJun 30, 2026
Nomura Small Cap Growth Fund1.08MUS$23.3MJun 30, 2026
SmallCap Fund1.03MUS$23.3MJul 31, 2026
Vanguard Small-Cap Growth Index Fund1.01MUS$21.7MJun 30, 2026
Vanguard Explorer Fund994KUS$22.4MJul 31, 2026
Harbor Small Cap Growth Fund962KUS$21.7MJul 31, 2026
Columbia Small Cap Growth Fund883KUS$13.4MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account814KUS$17.5MJun 30, 2026
Nuveen Quant Small Cap Equity Fund792KUS$17.9MJul 31, 2026
MFS New Discovery Fund786KUS$11.9MMay 31, 2026
Vanguard Russell 2000 Index Fund768KUS$11.6MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF642KUS$13.8MJun 30, 2026
Fidelity Extended Market Index Fund613KUS$9.29MMay 31, 2026
Invesco V.I. Main Street Small Cap Fund613KUS$13.1MJun 30, 2026
Schwab U.S. Small-Cap ETF572KUS$8.67MMay 31, 2026
Wasatch Ultra Growth Fund562KUS$12MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.458KUS$9.83MJun 30, 2026
Aristotle Core Equity Fund456KUS$9.79MJun 30, 2026
BlackRock Advantage Small Cap Core Fund394KUS$5.97MMay 29, 2026
Schwab Small-Cap Index Fund374KUS$8.45MJul 31, 2026
Vanguard Strategic Equity Fund368KUS$7.9MJun 30, 2026
Columbia Large Cap Growth Opportunity Fund349KUS$5.29MMay 31, 2026
Vanguard Health Care Index Fund344KUS$5.22MMay 31, 2026
First Trust Small Cap Growth AlphaDEX Fund327KUS$7.39MJul 31, 2026
Driehaus Micro Cap Growth Fund319KUS$6.84MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.314KUS$6.73MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund302KUS$6.82MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.293KUS$6.28MJun 30, 2026
MFS New Discovery Series283KUS$6.08MJun 30, 2026
Master Small Cap Index Series282KUS$6.06MJun 30, 2026
Optimum Small-Mid Cap Growth Fund282KUS$6.05MJun 30, 2026
Vanguard Strategic Small-Cap Equity Fund280KUS$6.01MJun 30, 2026
Victory RS Small Cap Growth Fund274KUS$5.88MJun 30, 2026
MassMutual Small Cap Opportunities Fund257KUS$5.52MJun 30, 2026
Lord Abbett Micro-Cap Growth Fund247KUS$5.58MJul 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund247KUS$5.29MJun 30, 2026
Fidelity Total Market Index Fund224KUS$3.39MMay 31, 2026
Alger Small Cap Growth Fund223KUS$5.04MJul 31, 2026

This page holds 50 of 277 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Rubinstein Julie
Officer: President and COO
Sale11,466USD 28.93US$332KNov 13, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 29.40US$349KNov 12, 2026
Rubinstein Julie
Officer: President and COO
Sale4,983USD 30.29US$151KNov 11, 2026
Rubinstein Julie
Officer: President and COO
Sale6,898USD 31.22US$215KNov 11, 2026
Bobulsky Susan
Officer: Chief Commercial Officer, MRD
Sale1,875USD 32.00US$60,000Nov 11, 2026
Rubinstein Julie
Officer: President and COO
Sale9,981USD 29.35US$293KNov 10, 2026
Rubinstein Julie
Officer: President and COO
Sale1,900USD 30.41US$57,779Nov 10, 2026
Rubinstein Julie
Officer: President and COO
Sale1,100USD 28.87US$31,757Nov 9, 2026
Rubinstein Julie
Officer: President and COO
Sale8,381USD 30.15US$253KNov 9, 2026
Rubinstein Julie
Officer: President and COO
Sale2,400USD 30.58US$73,392Nov 9, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Rubinstein Julie
Officer: President and COO
Sale3,481USD 27.88US$97,050Nov 6, 2026
Rubinstein Julie
Officer: President and COO
Sale8,400USD 27.32US$229KNov 6, 2026
Rubinstein Julie
Officer: President and COO
Sale5,926USD 26.10US$155KNov 5, 2026
Rubinstein Julie
Officer: President and COO
Sale5,455USD 26.88US$147KNov 5, 2026
Rubinstein Julie
Officer: President and COO
Sale500USD 27.70US$13,850Nov 5, 2026
Rubinstein Julie
Officer: President and COO
Sale4,000USD 25.78US$103KNov 4, 2026
Rubinstein Julie
Officer: President and COO
Sale7,881USD 26.60US$210KNov 4, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 25.98US$309KNov 3, 2026
Rubinstein Julie
Officer: President and COO
Sale9,296USD 25.23US$235KNov 2, 2026
Rubinstein Julie
Officer: President and COO
Sale2,585USD 26.34US$68,089Nov 2, 2026
Rubinstein Julie
Officer: President and COO
Sale9,486USD 26.55US$252KOct 30, 2026
Rubinstein Julie
Officer: President and COO
Sale2,395USD 27.45US$65,743Oct 30, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 28.27US$336KOct 29, 2026
Rubinstein Julie
Officer: President and COO
Sale11,681USD 28.44US$332KOct 28, 2026
Rubinstein Julie
Officer: President and COO
Sale200USD 28.90US$5,780Oct 28, 2026
Rubinstein Julie
Officer: President and COO
Sale3,000USD 26.58US$79,740Oct 27, 2026
Rubinstein Julie
Officer: President and COO
Sale8,881USD 27.53US$244KOct 27, 2026
Rubinstein Julie
Officer: President and COO
Sale8,503USD 25.94US$221KOct 26, 2026
Rubinstein Julie
Officer: President and COO
Sale3,378USD 26.30US$88,841Oct 26, 2026
Rubinstein Julie
Officer: President and COO
Sale4,500USD 24.50US$110KOct 23, 2026
Rubinstein Julie
Officer: President and COO
Sale7,381USD 25.28US$187KOct 23, 2026
Rubinstein Julie
Officer: President and COO
Sale10,181USD 24.38US$248KOct 22, 2026
Rubinstein Julie
Officer: President and COO
Sale1,700USD 25.29US$42,993Oct 22, 2026
Rubinstein Julie
Officer: President and COO
Sale5,999USD 25.25US$151KOct 21, 2026
Rubinstein Julie
Officer: President and COO
Sale5,882USD 25.57US$150KOct 21, 2026
Rubinstein Julie
Officer: President and COO
Sale11,781USD 24.53US$289KOct 20, 2026
Rubinstein Julie
Officer: President and COO
Sale100USD 24.85US$2,485Oct 20, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 24.05US$286KOct 19, 2026
Rubinstein Julie
Officer: President and COO
Sale11,581USD 24.21US$280KOct 16, 2026
Rubinstein Julie
Officer: President and COO
Sale300USD 25.45US$7,635Oct 16, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 25.61US$304KOct 15, 2026
Rubinstein Julie
Officer: President and COO
Sale6,781USD 25.57US$173KOct 14, 2026
Rubinstein Julie
Officer: President and COO
Sale5,100USD 25.82US$132KOct 14, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 25.50US$303KOct 13, 2026
Rubinstein Julie
Officer: President and COO
Sale9,181USD 25.35US$233KOct 12, 2026
Rubinstein Julie
Officer: President and COO
Sale2,700USD 26.07US$70,389Oct 12, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 26.41US$314KOct 9, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 25.66US$305KOct 8, 2026
Rubinstein Julie
Officer: President and COO
Sale11,881USD 26.40US$314KOct 7, 2026
Rubinstein Julie
Officer: President and COO
Sale9,381USD 27.36US$257KOct 6, 2026

This page holds 50 of 122 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Viking Global Investors LP18.80%30MMar 31, 2026Schedule 13G
BlackRock, Inc.7.90%12MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Hershberg
Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Recursion Pharmaceuticals, Inc. (Board Member · Since at least Apr 15, 2021); ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past)
Board Member · Since at least Jun 26, 2019
Kevin T Conroy
Other companies: Abbott Laboratories (Director · Since at least Apr 24, 2026); American Exceptionalism Acquisition Corp. A (Director · Since at least Sep 25, 2025); Align Technology, Inc. (Director · Since at least Dec 5, 2023); EXACT Sciences Corporation (President and CEO, Director · Since at least Mar 18, 2009); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Epizyme Inc (Director · Feb 6, 2017 – Aug 12, 2022 · Past)
Director · Jun 26, 2019 – Mar 6, 2023 · Past
Eric Dobmeier
Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past)
Director · Jun 26, 2019 – Feb 14, 2021 · Past
Chad Cohen
Other companies: Grindr Inc. (Director · Since at least Jul 30, 2024); Vacasa Inc (Director · Dec 7, 2021 – Apr 30, 2025 · Past); Trupanion, Inc. (Director · Dec 7, 2015 – Mar 31, 2019 · Past); Zillow Group, Inc. (CFO & Treasurer · Mar 1, 2011 – Feb 17, 2015 · Past)
Chief Financial Officer · Jun 26, 2019 – Dec 22, 2021 · Past
David E Goel
Other companies: Alumis Inc. (Director · Jun 27, 2024 – May 21, 2025 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Zentalis Pharmaceuticals, Inc. (Director · Apr 3, 2020 – Apr 3, 2020 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past)
Director · Jun 26, 2019 – Feb 15, 2021 · Past
Leslie Trigg
Other companies: EXACT Sciences Corporation (Director · Since at least Apr 29, 2025); Outset Medical, Inc. (Chair and CEO · Since at least Aug 17, 2020); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); Cardiovascular Systems Inc (Director · Aug 31, 2012 – Nov 18, 2016 · Past)
Director · Mar 17, 2021 – Mar 6, 2023 · Past
Peter Neupert
Other companies: Fortrea Holdings Inc. (Director · Since at least Jun 29, 2023); Labcorp Holdings Inc. (Director · Since at least Jan 1, 2013); Nextgen Healthcare Inc (Director · Aug 15, 2013 – Aug 15, 2013 · Past); Aquantive Inc (Director · May 10, 2006 – May 10, 2006 · Past)
Board Member · Since at least Jun 26, 2019
Chad Robins
Other companies: CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Cerevel Therapeutics Holdings Inc (Director · Jun 4, 2020 – Jun 4, 2020 · Past)
Chief Executive Officer, Co-founder, Chairman of the Board · Since at least Jun 26, 2019
Michelle Griffin
Other companies: Acer Therapeutics Inc (Director · Mar 14, 2023 – Mar 14, 2023 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past)
Board Member · Since at least Mar 6, 2023
Harlan S Robins
Other companies: CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past)
Chief Scientific Officer · Since at least Jun 26, 2019
All 32 people
PersonSeat
Michael J Pellini
Other companies: Singular Genomics Systems Inc (Director · May 29, 2024 – Feb 21, 2025 · Past)
Director · Mar 4, 2024 – Mar 4, 2025 · Past
ADAPTIVE INVESTORSKarina CalzadillaVice President, Investor Relations and FP& · Since at least Apr 15, 2026
ADAPTIVE MEDIAErica JonesAssociate Corporate Communications · Since at least Apr 15, 2026
Andris A ZoltnersDirector · Jun 26, 2019 – Feb 13, 2020 · Past
Clarice McCauleyVP, Head of Legal · Since at least Nov 5, 2026
Ed MoyleChief Information Security Officer · Dec 2, 2025 – Nov 5, 2026 · Past
Erica JonesAssociate Corporate Communications Director · Since at least Oct 14, 2026
Francis LoChief People Officer · Since at least Jun 26, 2019
Jim SnookSenior Vice President, Global Sales · Mar 5, 2026 – Nov 5, 2026 · Past
Julie RubinsteinPresident & Chief Operating Officer · Since at least Jun 26, 2019
Karina CalzadillaVice President, Investor Relations and FP&A · Since at least Oct 14, 2026
Katey OwenBoard Member · Since at least Mar 17, 2021
Kyle PiskelChief Financial Officer · Since at least Jun 26, 2019
Lance BaldoChief Medical Officer · Jun 26, 2019 – Mar 8, 2022 · Past
Mary Pat LancelottaSenior Vice President, Global Market and Business Development · Since at least Jun 30, 2026
Nancy Louise HillEVP, Operations & Program Mana · Jun 26, 2019 – Jan 19, 2021 · Past
Nitin SoodChief Commercial Officer, MRD · Aug 4, 2021 – Aug 7, 2023 · Past
R Mark AdamsChief Operating Officer · Apr 6, 2020 – Apr 10, 2023 · Past
Sharon BenzenoChief Commercial Officer, Immune Medicine · Since at least Jun 26, 2019
Stacy L TaylorSVP and General Counsel · Jan 8, 2020 – Aug 22, 2024 · Past
Susan BobulskyChief Commercial Officer, MRD · Since at least Aug 6, 2020
Tycho PetersonChief Financial Officer · Jun 1, 2022 – Mar 4, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Adaptive Biotechnologies Corporation.